Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease resulting from inappropriate immune responses and is characterized by diarrhea and bloody stools. Currently, numerous biologics and small-molecule agents have been developed and have improved outcomes in patients with UC. 1 Interleukin-23 (IL-23), a hetero...